Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosite Charts. Click Here for more Biosite Charts.](/p.php?pid=staticchart&s=N%5EBSTE&p=8&t=15)
SIRS-Lab GmbH entered into a collaboration agreement
with the U.S.-based bio-medical company, Biosite(R) Incorporated
(NASDAQ:BSTE) for the evaluation and potential commercialization of
sepsis markers.
Under the collaboration, SIRS-Lab will provide access to selected
biomarkers for sepsis. Biosite will then make antibodies to those
selected targets using the Company's proprietary antibody development
process, which combines immunization of mice and phage display to
generate highly diverse libraries of Omniclonal(R) antibodies with
high affinity and low cross-reactivity. The antibodies will be used to
generate assays for the measurement of the selected biomarker targets
in blood samples. Validated biomarkers will then be assessed for
commercialization potential, with high-value markers added to
Biosite's product development process.
"We are delighted to work with Biosite to evaluate the potential
value of our sepsis biomarkers for clinical diagnostic applications,"
said Dr. Stefan Russwurm, SIRS-Lab's chief executive officer. "This
agreement combines the strengths of both companies: Biosite's proven
antibody development and commercialization process for diagnostic
products with our expertise in molecular medicine concerning
inflammatory diseases."
"Our Biosite Discovery program is focused on diseases for which
rapid and accurate diagnostic tests are needed. Our antibody
technology allows us to quickly and economically evaluate potential
biomarkers for new tests," said Gunars Valkirs, Ph.D., senior vice
president Biosite Discovery.
"We value SIRS-Lab's competence in the identification of
biomarkers and we are pleased to have access to their intellectual
property in the area of sepsis."
The financial terms of the agreement were not disclosed.
About SIRS-Lab
SIRS-Lab, a research driven diagnostics company located in the
BioInstrumentation Center in Jena/Germany, is focused on the
identification, development and commercialization of novel,
proprietary biomarkers. Those biomarkers provide a basis for the
development of diagnostic systems for the early identification of
inflammatory/ immunological host responses as well as for the early
identification of the bacterial causes of infection. SIRS-Labs mission
is the development of new diagnostic systems for clinical routine
diagnostic and therapy monitoring of sepsis and acute inflammatory
diseases. Information on SIRS-Lab can be found at
http://www.sirs-lab.com/.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company
commercializing proteomics discoveries for the advancement of medical
diagnosis. The Company's products contribute to improvements in
medical care by aiding physicians in the diagnosis of critical
diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50
percent of U.S. hospitals and in more than 50 international markets.
Information on Biosite can be found at www.biosite.com.
Except for the historical information presented herein, matters
discussed in this press release are forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements
expressed or implied by such statements. Statements that are not
historical facts, including but not limited to statements that are
preceded by, followed by, or that include the words "will";
"believes"; "should"; "intends"; "anticipates"; "plans"; "expects";
"estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the potential
benefits of the collaboration and license agreement between Biosite
and SIRS-Lab, Biosite's ability to generate antibody libraries of
selected targets and evaluate the diagnostic utility of the targets,
Biosite's ability to develop and commercialize potential products
based on selected targets and Biosite's ability to incorporate any
licensed targets into its product development pipeline. Risks that
should be considered include risks and uncertainties regarding the
discovery and product development process generally, risks associated
with the introduction of competitive products from companies with
greater capital and resources, uncertainties around the proprietary
nature of the targets subject to the collaboration, expansion or
development of a direct sales effort in domestic and international
markets, and risks and expenses associated with litigation, contract
disputes, patent conflicts, product recalls, manufacturing
constraints, backlog, delays or inefficiencies, shipment problems,
seasonal customer demand, the timing of significant orders, changes in
reimbursement policies, regulatory changes, competitive pressures on
average selling prices, and the other risks detailed in Biosite's most
recent Annual Report on Form 10-K, as amended, Quarterly Report on
Form 10-Q, and other SEC filings. Biosite disclaims, any intent or
obligation to update these forward-looking statements. Copies of
Biosite's public disclosure filings are available from its investor
relations department.
Biosite(R), Omniclonal(R), Triage(R) and New Dimensions in
Diagnosis(R) are registered trademarks of Biosite Incorporated. The
Company's logo is a trademark of Biosite Incorporated.